[Translation] A single-dose, randomized, open-label, crossover, two-formulation, postprandial human bioequivalence study of relugoli tablets in healthy subjects.

考察参比制剂与受试制剂在健康人体内的生物等效性和安全性。

[Translation]

The bioequivalence and safety of the reference formulation and the test formulation in healthy human subjects were investigated.

Start Date11 May 2026

Sponsor / Collaborator

Hangzhou Minsheng Pharmaceutical Co., Ltd.

NCT07455903

/ RecruitingPhase 2IIT

Assessing the Efficacy of Neoadjuvant Androgen Deprivation Therapy (ADT) Utilizing 18F-Flotufolastat PSMA PET/CT in Patients With High-Risk Localized Prostate Cancer (LHRPC)

The purpose of this research study is to test the efficacy of ADT on prostate-specific membrane antigen (PSMA), a marker of prostate cancer, before and after scheduled ADT. Follow up will be 48 months your prostate removal to do a blood test and log if any new or worsening symptoms have occurred as a part of your standard-of-care (SOC).

Start Date23 Apr 2026

Sponsor / Collaborator

Baptist Health South Florida, Inc.

[+1]

CTR20260464

/ Active, not recruitingNot Applicable

瑞卢戈利片在健康受试者中的单剂量、随机、开放、交叉、两制剂、空腹人体生物等效性试验

[Translation] A single-dose, randomized, open-label, crossover, two-formulation, fasting human bioequivalence study of relugoli tablets in healthy subjects.

考察参比制剂与受试制剂在健康人体内的生物等效性和安全性。

[Translation]

The bioequivalence and safety of the reference formulation and the test formulation in healthy human subjects were investigated.

Start Date02 Mar 2026

Sponsor / Collaborator

Hangzhou Minsheng Pharmaceutical Co., Ltd.

100 Clinical Results associated with Relugolix

100 Translational Medicine associated with Relugolix

100 Patents (Medical) associated with Relugolix

235

Literatures (Medical) associated with Relugolix

31 Dec 2026·GYNECOLOGICAL ENDOCRINOLOGY

Relugolix combination therapy in symptomatic adenomyosis and uterine fibroids: a case series

Article

Author: Angioni, Stefano ; Chilà, Caterina ; Di Michele, Stefano ; Saponara, Stefania ; Muzii, Ludovico ; D'Alterio, Maurizio Nicola ; Vignali, Michele ; Maiorana, Antonio

OBJECTIVE:

To evaluate the clinical efficacy and safety of a once-daily oral fixed-dose combination of relugolix 40 mg, estradiol 1 mg, and norethisterone acetate 0.5 mg in women with symptomatic adenomyosis coexisting with uterine fibroids.

METHODS:

This case series included six women with uterine fibroids and concomitant adenomyosis, diagnosed by transvaginal ultrasound according to MUSA criteria. All patients received continuous treatment for 12 months. Clinical outcomes included changes in dysmenorrhea and pelvic pain assessed by the Visual Analogue Scale (VAS), menstrual blood loss evaluated through the Pictorial Blood Assessment Chart (PBAC), and hemoglobin levels. Ultrasonographic assessment measured uterine volume and adenomyosis-related features before and after treatment.

RESULTS:

All patients achieved complete resolution of dysmenorrhea and chronic pelvic pain, with VAS scores reduced to zero. Menstrual bleeding ceased in all cases (PBAC = 0), and hemoglobin levels improved after 12 months. Ultrasound examination demonstrated a reduction in uterine volume ranging from 8.6% to 58.3%, along with partial regression of direct adenomyotic features. No adverse events or treatment discontinuations were reported during follow-up.

CONCLUSIONS:

Relugolix/estradiol/norethisterone acetate combination therapy was effective, well-tolerated, and associated with consistent clinical and sonographic improvement in women with adenomyosis and coexisting fibroids. Future larger-scale, controlled studies with extended follow-up are warranted to validate these findings.

01 Jul 2026·Annals of African Medicine

Relugolix for Metastatic Hormone-sensitive Prostate Cancer with Impending Paraplegia

Article

Author: Rahman, Ziaur ; Jain, Raajul ; Kumar, Prem ; Prem, Pragya

Abstract:

Luteinizing hormone-releasing hormone agonists, used in advanced prostate cancer, can cause an initial testosterone surge and may inadequately suppress follicle-stimulating hormone, potentially promoting tumor growth. Injectable gonadotropin-releasing hormone (GnRH) antagonists avoid this surge but have drawbacks like injection-site reactions and monthly dosing. Relugolix, an oral GnRH antagonist, offers rapid testosterone suppression without flare and reduced cardiovascular risks. We report a 72-year-old man with suspected metastatic prostate cancer, presenting with severe neuritic pain and lower limb weakness. Relugolix, started before biopsy along with zoledronic acid and steroids, led to symptom relief within 24 h. This case supports Relugolix’s utility in urgent hormone-sensitive metastatic prostate cancer care.

01 May 2026·Urology Practice

Letter: Adherence and Persistence on Relugolix for the Treatment of Prostate Cancer in the United States Medicare Fee-for-Service Population

Letter

Author: Sears, Carly ; Watson, Robert ; Schellhammer, Paul ; Wassersug, Richard

108

News (Medical) associated with Relugolix

18 May 2026

·www.biospace.com

New Data from Sumitomo Pharma America at AUA 2026 Highlight Efficacy of Vibegron in Men Aged 75 and Older with Overactive Bladder and BPH

SMPA reinforces commitment to the urology community with findings from studies across overactive bladder and advanced prostate cancer portfolios MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Sumitomo Pharma America, Inc. (SMPA) today announced the presentation of new data from its urology and oncology portfolios at the American Urological Association (AUA) 2026 Annual Meeting, held on May 15–18 in Washington, D.C. The presentations include a featured subgroup analysis of the phase 3 COURAGE trial evaluating vibegron in older men, along with real-world evidence from the OPTYX study of relugolix in advanced prostate cancer. “Our presence at AUA 2026 underscores our deep-rooted commitment to advancing scientific understanding for patients managing complex urologic conditions,” said Tsutomu Nakagawa, Ph.D., President and Chief Executive Officer of SMPA. “By focusing on patient populations at particular risk, such as men over 75 with overactive bladder and on pharmacologic treatment for benign prostatic hyperplasia, and those navigating the complexities of advanced prostate cancer, we aim to provide clinicians with the robust data they need to make informed, patient-centered treatment decisions.” Safety and efficacy outcomes with vibegron are comparable in older and younger patients Data presented includes a poster on a subgroup analysis of the placebo-controlled phase 3 COURAGE trial, which evaluated the efficacy and safety of once-daily vibegron 75 mg in men with symptoms of overactive bladder (OAB) who were also receiving pharmacologic therapy for benign prostatic hyperplasia (BPH) (stable dose of α-blocker ± 5α-reductase inhibitors). The analysis found that men ≥75 years experienced clinically meaningful reductions from baseline at week 24 in average daily number of micturitions and urgency episodes with vibegron (n=92) compared with placebo (n=100). Micturitions were –2.3 in the vibegron group compared with –1.5 in the placebo group, and urgency episodes were –3.6 in the vibegron group compared with –2.3 in the placebo group. These results were comparable to the outcomes observed in men <75 years. Vibegron was generally well tolerated in this older population, with a safety pro to that observed in men <75 years. “Older men often face the dual challenge of managing OAB symptoms while on existing therapies for BPH. These findings are encouraging as they demonstrate that vibegron can provide meaningful symptomatic relief in this specific, often harder-to-treat population, with a safety pro to that of younger patients,” said Dr. Sender Herschorn, M.D., Professor of Surgery/Urology at the University of Toronto and lead author of the poster. Additional data presented in treatment of OAB and advanced prostate cancer In a separate podium presentation, SMPA shared a subgroup analysis from the COURAGE trial evaluating the effect of vibegron on sexual function in men. SMPA, in a poster presentation, also shared an interim analysis of testosterone suppression and recovery from the OPTYX study, a prospective, long-term observational study of relugolix (monotherapy and combination) in a real-world setting. Presentation Details Title Details IP15-20: Efficacy and safety of vibegron in men ≥75 years of age with symptoms of overactive bladder on pharmacotherapy for benign prostatic hyperplasia: a subgroup analysis of the COURAGE trial Poster Presentation Presenter: Dr. Sender Herschorn, MD, University of Toronto IP38-21: Testosterone suppression and recovery in patients with advanced prostate cancer treated with relugolix: an interim analysis of the OPTYX study Poster Presentation Presenter: Dr. Benjamin Lowenritt, MD, FACS, Chesapeake Urology PD26-08: Evaluating sexual function in men treated with vibegron for overactive bladder while on pharmacological therapy for benign prostatic hyperplasia: exploratory analysis from the phase 3 COURAGE trial Podium Presentation Presenter: Dr. Kenneth Peters, MD, Urology, Corewell Health William Beaumont University Hospital About GEMTESA ® (vibegron) In the U.S., GEMTESA (vibegron) has been indicated for the treatment of OAB with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults since December 2020. GEMTESA was approved in December 2024, for overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adult males on pharmacological therapy for benign prostatic hyperplasia (BPH). GEMTESA works by selectively targeting beta-3 adrenergic receptors to reduce OAB symptoms through the relaxation of the bladder detrusor muscle to increase capacity. About Overactive Bladder Overactive bladder (OAB) is a clinical condition that occurs when the bladder muscle contracts involuntarily. Symptoms may include urinary urgency (the sudden urge to urinate that is difficult to control), urgency incontinence (unintentional loss of urine immediately after an urgent need to urinate), and frequent urination (usually eight or more times in 24 hours). 1 Approximately 33 million U.S. adults experience the bothersome symptoms of OAB. 2 INDICATIONS AND USAGE GEMTESA ® is a beta-3 adrenergic agonist indicated for the treatment of: overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults. overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adult males on pharmacological therapy for benign prostatic hyperplasia (BPH). IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS GEMTESA is contraindicated in patients with known hypersensitivity to vibegron or any components of GEMTESA. Hypersensitivity reactions, such as angioedema, have occurred. WARNINGS AND PRECAUTIONS Urinary Retention Urinary retention has been reported in patients taking GEMTESA. The risk of urinary retention may be increased in patients with bladder outlet obstruction and also in patients taking muscarinic antagonist medications for the treatment of OAB. Monitor patients for signs and symptoms of urinary retention, particularly in patients with bladder outlet obstruction or patients taking muscarinic antagonist medications for the treatment of OAB. Discontinue GEMTESA in patients who develop urinary retention. Angioedema Angioedema of the face and/or larynx has been reported with GEMTESA. Angioedema has been reported to occur hours after the first dose or after multiple doses. Angioedema, associated with upper airway swelling, may be life-threatening. If involvement of the tongue, hypopharynx, or larynx occurs, immediately discontinue GEMTESA and provide appropriate therapy and/or measures necessary to ensure a patent airway. ADVERSE REACTIONS Most common adverse reactions (≥2%) reported with GEMTESA were headache, urinary tract infection, nasopharyngitis, diarrhea, nausea, and upper respiratory tract infection. Please see full Prescribing Information . ABOUT ORGOVYX ® (relugolix) ORGOVYX ® (relugolix) is a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of adult patients with advanced prostate cancer. IMPORTANT SAFETY INFORMATION Contraindication ORGOVYX is contraindicated in patients with severe hypersensitivity to relugolix or to any of the product components. Warnings and Precautions QT/QTc Interval Prolongation: Androgen deprivation therapy, such as ORGOVYX, may prolong the QT/QTc interval. Providers should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, or frequent electrolyte abnormalities and in patients taking drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected. Consider periodic monitoring of electrocardiograms and electrolytes. Hypersensitivity: Angioedema was reported in 0.2% of patients treated with ORGOVYX in HERO. Hypersensitivity reactions, including pharyngeal edema and other serious cases of angioedema, have been reported post-marketing with ORGOVYX. Advise patients who experience any symptoms of hypersensitivity to temporarily discontinue ORGOVYX and promptly seek medical care. Discontinue ORGOVYX for severe hypersensitivity reactions and manage as clinically indicated. Embryo-Fetal Toxicity: The safety and efficacy of ORGOVYX have not been established in females. Based on findings in animals and mechanism of action, ORGOVYX can cause fetal harm and loss of pregnancy when administered to a pregnant female. Advise males with female partners of reproductive potential to use effective contraception during treatment and for 2 weeks after the last dose of ORGOVYX. Laboratory Testing: Therapy with ORGOVYX results in suppression of the pituitary gonadal system. Results of diagnostic tests of the pituitary gonadotropic and gonadal functions conducted during and after ORGOVYX may be affected. The therapeutic effect of ORGOVYX should be monitored by measuring serum concentrations of prostate-specific antigen (PSA) periodically. If PSA increases, serum concentrations of testosterone should be measured. Adverse Reactions Serious adverse reactions occurred in 12% of patients receiving ORGOVYX. Serious adverse reactions in ≥0.5% of patients included myocardial infarction (0.8%), acute kidney injury (0.6%), arrhythmia (0.6%), hemorrhage (0.6%), and urinary tract infection (0.5%). Fatal adverse reactions occurred in 0.8% of patients receiving ORGOVYX including metastatic lung cancer (0.3%), myocardial infarction (0.3%), and acute kidney injury (0.2%). Fatal and non-fatal myocardial infarction and stroke were reported in 2.7% of patients receiving ORGOVYX. Most common adverse reactions (≥10%) and laboratory abnormalities (≥15%) in patients receiving ORGOVYX were hot flush (54%), glucose increased (44%), triglycerides increased (35%), musculoskeletal pain (30%), hemoglobin decreased (28%), alanine aminotransferase increased (27%), fatigue (26%), aspartate aminotransferase increased (18%), constipation (12%), and diarrhea (12%). Drug Interactions Co-administration of ORGOVYX with an oral P-gp inhibitor increases relugolix exposure, which may increase the risk of adverse reactions associated with ORGOVYX. Avoid co-administration of ORGOVYX with oral P-gp inhibitors. If co-administration is unavoidable, take ORGOVYX first and separate dosing by at least 6 hours. Monitor patients for increased adverse reactions. Treatment with ORGOVYX may be interrupted for up to 2 weeks if a short course of treatment with a P-gp inhibitor is required. Resume ORGOVYX after the P-gp inhibitor is discontinued. If treatment with ORGOVYX is interrupted for greater than 7 days, restart ORGOVYX with a 360 mg loading dose on the first day and continue with 120 mg once daily. Co-administration of ORGOVYX with a combined P-gp and strong CYP3A inducer decreases relugolix exposure, which may reduce the effects of ORGOVYX. Avoid co-administration of ORGOVYX with combined P-gp and strong CYP3A inducers. If co-administration is unavoidable, increase the ORGOVYX dose to 240 mg once daily. After discontinuation of the combined P-gp and strong CYP3A inducer, resume the recommended ORGOVYX dose of 120 mg once daily. Please see full Prescribing Information for ORGOVYX. About Sumitomo Pharma Sumitomo Pharma Co., Ltd. is a global pharmaceutical company based in Japan with key operations in the U.S. (Sumitomo Pharma America, Inc.) focused on addressing patient needs in oncology, urology, women's health, rare diseases, cell & gene therapies and CNS. With products in the U.S., Canada, and Europe, and a diverse pipeline of early- to late-stage assets, we aim to accelerate discovery, research, and development to bring novel therapies to patients sooner. For more information on SMPA, visit our website or follow us on LinkedIn . The Sumitomo corporate symbol mark is a registered trademark of Sumitomo Pharma Co., Ltd., used under license. SUMITOMO PHARMA is a trademark of Sumitomo Pharma Co., Ltd., used under license. SUMITOMO is a registered trademark of Sumitomo Chemical Co., Ltd., used under license. Sumitomo Pharma America, Inc. is a U.S. subsidiary of Sumitomo Pharma Co., Ltd. GEMTESA and the GEMTESA logo are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries. ORGOVYX ® and its logo are registered trademarks of Sumitomo Pharma Co. Ltd., used under license. ©2026 Sumitomo Pharma America, Inc. All rights reserved. References Overactive bladder – symptoms and causes. Mayo Clinic. February 4, 2025. Accessed May 6, 2026. Gomelsky A, Dmochowski RR. Update on the management of overactive bladder: patient considerations and adherence. Open Access J Urol. 2011;3:7-17. doi:10.2147/OAJU.S7233 GEMTESA. Prescribing Information. Marlborough, MA; Sumitomo Pharma America; 2025 Contacts For further information: SMPA CONTACT: Dave Murdoch, Sumitomo Pharma America, Inc., david.murdoch@us.sumitomo-pharma.com , +1 (774) 405-5570

Clinical ResultPhase 3Drug Approval

17 Apr 2026

·endpoints.news

Novartis' Vas Narasimhan heads to Anthropic's board; Metsera alum joins Structure as COO

→ Anthropic keeps deepening its ties to the biopharma industry, appointing Novartis CEO Vas Narasimhan to its board. The AI giant recently acquired Coefficient Bio , a New York-based stealth AI biotech. Narasimhan, who has led Novartis since 2018 and previously served as PhRMA’s chair, will bring a healthcare industry perspective to a board that also includes former Microsoft and General Motors CFO Chris Liddell , and Netflix co-founder Reed Hastings . → Obesity pill developer Structure Therapeutics has hired Matthew Lang as COO and general counsel. Lang was most recently chief legal officer at obesity player Metsera , where he helped choreograph the biotech’s acquisition by Pfizer for $7.6 billion upfront last year. Perhaps Structure is contemplating a similar deal, or perhaps it felt it needed a new lawyer on board after Novo Nordisk ’s recent legal travails. Novo was forced to sue Hims & Hers alleging patent infringement after the compounder launched a copycat of its oral Wegovy pill in February. The two companies eventually reached a truce, but Structure might want to guard against a similar situation emerging if its GLP-1 pill, called aleniglipron , gains approval too. The asset recently generated highly promising Phase 2 data. Lang spent more than six years with Myovant and helped guide the development, approval and sale of endometriosis drug Myfembree and prostate cancer therapy Orgovyx . He was also chief business and legal officer at Lyell Immunopharma . → ADC specialist Kivu Bioscience had been operating without a CEO since it spun out of Synaffix in 2024 . But president and COO Mohit Trikha has been the voice of the company from the beginning, and his appointment as CEO this week was billed as a “natural next step” by chairman Daniel O’Connell . Trikha has pharma experience from AbbVie as its head of oncology early development from 2017-22, and he was also a venture partner at Apple Tree Partners , which has since filed for bankruptcy. He used to sit on the board at Replicate Bioscience and Galvanize Therapeutics , two biotechs from the ATP portfolio. → Cardiff Oncology has officially tapped Mani Mohindru as permanent CEO, and it has recruited Josh Muntner as CFO. When Cardiff released mixed Phase 2 data for its colorectal cancer drug onvansertib , Mohindru replaced Mark Erlander on an interim basis that same day and finance chief James Levine stepped down. Mohindru will keep her spot on the board of directors. Muntner held the CFO post at Imvax and Mesoblast before coming to Cardiff last week. He won’t be the new guy for much longer, because Ajay Aggarwal will become COO on April 27. Aggarwal has spent the last four and a half years with Aclaris Therapeutics as head of clinical development. → Prime Medicine is finally getting a new CFO in Svetlana Makhni , who is joining the gene editing company from Marengo Therapeutics . The move comes after Prime’s former finance chief Allan Reine became CEO last May as part of a broader revamp . Prime earlier this year reversed course and said it would continue to develop a previously shelved therapy for a rare condition called chronic granulomatous disease. The company also expects to enter the clinic soon for two liver disease programs. → Parabilis Medicines has introduced Helen Ho as chief business and strategy officer, and promoted Tom Kotarakos to CFO. Ho is the latest Blueprint Medicines exec to find a new home, serving as CBO until it was sold to Sanofi . “After taking some time off to reflect on what I wanted my next chapter to look like, I knew I wasn’t just looking for a role,” Ho wrote in a LinkedIn post . “For me, it’s identifying the right problem to solve, the very best people to solve it with, and the opportunity to be part of something truly extraordinary. This is what led me to Parabilis Medicines.” Kotarakos joined Mathai Mammen ’s crew as SVP of finance in 2021, when it was named FogPharma and led by Greg Verdine . Kotarakos’ LinkedIn page says he was elevated to CFO in February, a month after Parabilis announced a $305 million Series F. → Jack O’Meara ’s brain drug company Aerska has appointed co-founder Stuart Milstein as chief platform officer, and added Sonoma Biotherapeutics COO Lisa Taylor Ash to its board. Milstein brings RNA experience from Alnylam , Korro Bio and Sail Biomedicines . Aerska is developing targeted RNA treatments for brain diseases like Alzheimer’s and Parkinson’s, and debuted in October with $21 million in seed funding. → Corbus Pharmaceuticals medical chief Dominic Smethurst will resign on June 30, according to an SEC filing . Smethurst took this job in early 2024 after three years as CMO of Bicycle Therapeutics . Corbus reported Phase 1a data in December for its CB1 inverse agonist CRB-913 in obesity, and it’s also developing a Nectin-4 ADC called CRB-701 . → ALX Oncology ’s CD47 aspirations have run into some potholes , while other biotechs have similarly been foiled in the space. But the South San Francisco biotech keeps plugging away with evorpacept , and it’ll do so with Jeff Knight as chief development and operating officer. On April 10, Knight resigned from the same position at Crinetics Pharmaceuticals , which now sells the acromegaly treatment Palsonify . The Amgen vet was SVP, portfolio management, alliance management and corporate operations at the end of a three-year run with Poseida Therapeutics . → Zealand Pharma has signed up Eric Rojas as its new head of investor relations. Rojas joins the company at a tricky time: Its share price slid more than 30% after its Roche -partnered amylin analog posted weaker-than-expected mid-stage data last month. He has held senior investor relations positions at companies including Stoke Therapeutics , Vertex and Shire . Zealand has another shot on goal with its obesity and fatty liver disease drug survodutide , though that is being developed by Boehringer Ingelheim under the partners’ licensing deal. Phase 3 obesity data on survodutide, a GLP-1 and glucagon agonist, are due in the summer. → Harbour BioMed — Chinese biotech partner to the stars — has lined up Bristol Myers Squibb and Merck alum Adam Zong as president. Zong was the founding CEO of Hengrui Therapeutics in the US and then president and COO of Seven & Eight Biopharmaceuticals from 2017-21. Harbour BioMed has teamed up with Bristol Myers, AstraZeneca , Otsuka and others, with an R&D engine that’s humming along in I&I diseases and immuno-oncology. → As Idorsia searches for a CEO, Amer Joseph will go to the Swiss biotech on May 1 as CMO and head of global clinical development. Alberto Gimona , who worked with Jean-Paul Clozel at Actelion in the 2010s, is retiring after four years of leading global clinical development and seven years overall at Idorsia. Joseph handled global clinical development duties for Chiesi and had two separate stints at Bayer (with a brief stop at GSK in between). Clozel has filled in as interim CEO since Srishti Gupta ’s departure . → Evotec has made its second major hire this month, naming Ingrid Müller as COO. Müller was VP of portfolio strategy & execution at fellow German company CureVac until rival BioNTech bought the vaccine maker for $1.25 billion. She also spent eight years with Sanofi, culminating in her role as SVP, global procurement outsourcing & external manufacturing. While Müller starts her new job at Evotec on May 1, ex- Iktos CBO Ashiq Khan is settling in as chief commercial officer. → Matthew Gall is replacing Daniella Beckman as CFO of targeted cancer drug developer Tango Therapeutics . Gall is joining Tango after a brief stop at eye therapy developer Kalaris Therapeutics in the same role. Tango has also hired MorphoSys vets Yen-Ching Chua as chief development operations officer, and Janice Kapty as SVP of corporate strategy and project leadership. Tango’s shares $TNGX jumped 20% this week following a highly promising Phase 3 readout from Revolution Medicines ’ pancreatic cancer drug. Tango is studying its PRMT5 inhibitor vopimetostat in combination with Revolution Medicines’ treatments in both pancreatic and lung cancers, and expects to have initial data from that combination trial this year. → Charles Morris has replaced Jane Huang as CMO of Prelude Therapeutics , which shelved its SMARCA2 degrader program in favor of a KAT6A degrader to treat ER+ breast cancer. Morris took on the same responsibilities at Lava Therapeutics , Celyad Oncology and Radius Health . No word on what’s next for Huang, who joined Prelude in 2022 after six years at BeOne Medicines (then known as BeiGene ). → Former Acorda medical chief Burkhard Blan k has reunited with Ron Cohen at Oryon Cell Therapies . Blank will serve as Oryon’s CMO, leaving his post at MannKind Corporation . Oryon is one of a handful of biotech companies developing Parkinson’s cell therapies derived from stem cells. Blank brings experience developing Parkinson’s drugs from his time at Acorda, where he oversaw the Phase 3 program and approval for Inbrija , as well as from Boehringer Ingelheim. His new role comes after longtime Acorda leader Cohen joined Oryon as CEO earlier this year as the company raised $21 million. → Harmony Biosciences has followed up its appointment of COO Peter Anastasiou by hiring Glenn Reicin as finance chief. This is Reicin’s fourth CFO job this decade, following stops at Sigilon Therapeutics , now-defunct Alladapt Immunotherapeutics and AstraZeneca’s oral GLP-1 partner Eccogene . Reicin succeeds Sandip Kapadia , who had held this position for the past five years. → With the demise of iTeos Therapeutics behind her, Yvonne McGrath has moved on to French protein degradation biotech Enodia Therapeutics as CSO. McGrath was promoted to CSO at iTeos in 2022, but it had to shut down last year as the TIGIT field continues to take on water. Enodia kicked off 2026 with a €20.7 million seed round. → Wolfram Brugger has been named CMO at Swedish gene therapy maker Asgard Therapeutics . Brugger led clinical development at CAR-T cell therapy shop Autolus and helped develop the lymphoma drug tafasitamab at MorphoSys. Incyte shelled out $25 million for the full global rights to tafasitamab, now marketed as Monjuvi . Johnson & Johnson Innovation – JJDC and Novo Holdings contributed to Asgard’s €30 million Series A in March 2024. Is another round of financing on the horizon? → On the heels of Inhwan Kim ’s promotion, Boulder, CO biotech Enveda has installed Christopher Porter as SVP, clinical operations. Porter just completed a stint at Theravance Biopharma as VP of development strategy and innovation, and he arrives at a critical juncture after Enveda released the first clinical data for its atopic dermatitis hopeful ENV-294 . → Prothena has promoted Annie Kingston to chief strategy officer and Michael Isaacs to general counsel. Kingston celebrates her third anniversary with the company this month and she’s been VP, corporate strategy and chief of staff since March 2025. Isaacs was elevated to deputy general counsel in 2023 and he’ll get started in his new role when current legal chief Michael Malecek leaves in June. → Rytelo maker Geron has selected Tim Williams as chief legal officer. Williams had been busy with legal work as general counsel at Vanda Pharmaceuticals since 2018. Vanda’s motion sickness drug Nereus was approved as 2025 drew to a close, after the company dropped a lawsuit against the FDA over a partial clinical hold of the drug. → Adagene has welcomed ex- J&J oncology exec Peter Lebowitz to its scientific and strategic advisory board. Lebowitz runs Endpoints 11 winner Third Arc Bio , which raised a $165 million Series A in July 2024 and is partnering with Adagene on “masked” T cell engagers. → Ottimo Pharma CEO David Epstein has joined the board of directors at Frontier Medicines , which hasn’t pulled the trigger on an IPO yet and raised a Series C round in 2024. Epstein chairs the board at newly public biotech Agomab and ran Seagen when it was purchased by Pfizer. → In other boardrooms, Aktis Oncology is bringing in Daiichi Sankyo veteran Glenn Gormley , while Helen Kim and Oleg Nodelman will depart on May 26; Orum Therapeutics has added ex-Bicycle and Repare Therapeutics CMO Maria Koehler and Locust Walk ’s Geoff Meyerson ; Anika Therapeutics chair Cheryl Blanchard has clinched a spot at Xilio Therapeutics ; and Edwin Moses will be chairman of Oxford, UK-based Greywolf Therapeutics after chairing the board at Amgen’s M&A prize Dark Blue Therapeutics . Andrew Dunn contributed to this edition. Endpoints is fielding the next Biopharma Sentiment Index (BPSI) — a concise, three-minute survey that distills thousands of industry views into a clear quarterly benchmark. This year is pivotal for biopharma, and we need your perspective on where things are going. Take the survey here.

Executive ChangePhase 1AcquisitionPhase 3Drug Approval

15 Apr 2026

·www.biospace.com

Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel

SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the appointment of Matthew Lang, J.D. as Chief Operating Officer and General Counsel. Mr. Lang joins Structure Therapeutics with more than fifteen years of executive leadership experience across global biopharmaceutical organizations, with deep expertise spanning legal, corporate strategy, compliance, risk management, and business development. “Matt is a proven leader with a strong track record of guiding organizations through growth and transformation,” said Raymond Stevens, Ph.D., CEO of Structure Therapeutics. “His experience across global operations, strategic transactions, and commercialization will be critical as we move aleniglipron into Phase 3 and continue to build a world-class leadership team.” Mr. Lang most recently served as Chief Legal Officer and Secretary at Metsera, Inc., helping to guide the company through its up to $10 billion acquisition by Pfizer. Prior to Metsera, Mr. Lang served as Chief Business and Legal Officer at Lyell Immunopharma, Inc., and held several executive officer positions at Myovant Sciences, where he helped lead the company through Phase 3 clinical development, global approval and commercialization of Myfembree ® and Orgovyx ® . Mr. Lang also served as the Managing Director and General Manager of Myovant’s European operations in Basel Switzerland where he was responsible for all aspects of Myovant’s ex-US business operations. Earlier in his career Mr. Lang held roles of increasing seniority at Gilead Sciences, Inc., and was an attorney at Dechert, LLP. He received his B.A. in Classical Studies from Queen’s University at Kingston, Canada and his J.D. from the University of Pennsylvania Law School. “I am excited to join Structure Therapeutics at this important stage as we move into Phase 3 development with one of the most promising late-stage assets in the competitive obesity landscape,” said Mr. Lang. “The Company’s mission and differentiated portfolio represent a compelling opportunity to deliver a complete pipeline of meaningful therapies to patients. I look forward to working with the team to further strengthen the Company’s operational foundation, execute on strategic priorities, and drive long-term value.” About Structure Therapeutics Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more people living with obesity around the world. For additional information, please visit . Forward Looking Statements This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation, statements concerning: the Company’s future plans and prospects; and any expectations regarding the potential benefits, tolerability and safety profile, accessibility, scalability, combinability, capability, efficacy, convenience, expected effects and future application of aleniglipron and any other of the Company’s investigational compounds. In addition, when or if used in this press release, the words and phrases “anticipated,” “believe,” “expect,” “may,” “on track,” “plan,” “potential,” “suggests,” “to be,” “to begin,” “will,” and similar expressions and their variants, as they relate to the Company may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although the Company believes the expectations reflected in such forward-looking statements are reasonable, the Company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied in the Company’s forward-looking statements due to a variety of risks and uncertainties, which include, without limitation: risks and uncertainties related to potential delays in the commencement, enrollment and completion of the Company’s planned clinical studies; the Company’s ability to advance aleniglipron, ACCG-2671, ACCG-3535, ANPA-0073, LTSE-2578, and its other therapeutic candidates, obtain regulatory approval of, and ultimately commercialize the Company’s therapeutic candidates; competitive products or approaches limiting the commercial value of the Company’s product candidates; the Company’s ability to fund development activities and achieve development goals; and other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s latest Annual Report on Form 10-K and future reports the Company may the SEC from time to time. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. Investors: Corey Davis, Ph.D. LifeSci Advisors, LLC 212-915-2577 cdavis@lifesciadvisors.com Jun Yoon Structure Therapeutics Inc. ir@structuretx.com Media: Dan Budwick 1AB Dan@1abmedia.com

100 Deals associated with Relugolix

External Link

KEGG	Wiki	ATC	Drug Bank
D10888	Relugolix	L01XX	DB11853

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Advanced Prostate Carcinoma	Canada	Sumitomo Pharma Co., Ltd.	10 Oct 2023
Castration-sensitive prostate cancer	European Union	Accord Healthcare SL	29 Apr 2022
Castration-sensitive prostate cancer	Iceland	Accord Healthcare SL	29 Apr 2022
Castration-sensitive prostate cancer	Liechtenstein	Accord Healthcare SL	29 Apr 2022
Castration-sensitive prostate cancer	Norway	Accord Healthcare SL	29 Apr 2022
Endometriosis	Japan	ASKA Pharmaceutical Co., Ltd.	24 Dec 2021
Prostatic Cancer	United States	Sumitomo Pharma America, Inc.	18 Dec 2020
Leiomyoma	Japan	ASKA Pharmaceutical Co., Ltd.	08 Jan 2019

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Recurrent Prostate Carcinoma	Phase 3	United States	Pfizer Inc.	31 Jan 2025
Recurrent Prostate Carcinoma	Phase 3	United States	Sumitomo Pharma America, Inc.	31 Jan 2025
Dysmenorrhea	Phase 3	United States	Sumitomo Pharma Switzerland GmbH	01 Nov 2017
Dysmenorrhea	Phase 3	Australia	Sumitomo Pharma Switzerland GmbH	01 Nov 2017
Dysmenorrhea	Phase 3	Brazil	Sumitomo Pharma Switzerland GmbH	01 Nov 2017
Dysmenorrhea	Phase 3	Chile	Sumitomo Pharma Switzerland GmbH	01 Nov 2017
Dysmenorrhea	Phase 3	Czechia	Sumitomo Pharma Switzerland GmbH	01 Nov 2017
Dysmenorrhea	Phase 3	Italy	Sumitomo Pharma Switzerland GmbH	01 Nov 2017
Dysmenorrhea	Phase 3	New Zealand	Sumitomo Pharma Switzerland GmbH	01 Nov 2017
Dysmenorrhea	Phase 3	Poland	Sumitomo Pharma Switzerland GmbH	01 Nov 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05605964 (CTgov)	Phase 3	Prostatic Cancer	387	Relugolix (Relugolix)	ivpsxyrstz = pvhhkgeyyi mofebtywaz (absvxurgfd, jlvcbpipsm - uydwtiirkt) View more	-	15 Jun 2026
				Leuprolide Acetate (Leuprolide Acetate)	ivpsxyrstz = puaqmxzmwp mofebtywaz (absvxurgfd, pqgutoxppy - rlyacxprjj) View more
NCT05467176 (OPTYX, ASCO2026)	Not Applicable	Metastatic Prostate Carcinoma	255	Relugolix monotherapy	twfnwnihfd(ruerxafmaf) = etrynzxzis gxapcmxsty (rfqehbhdwn ) View more	Positive	29 May 2026
				Relugolix in combination with other systemic prostate therapies	twfnwnihfd(ruerxafmaf) = mjhtvzgvme gxapcmxsty (rfqehbhdwn ) View more
NCT07216248 (OPTIMAS, ASCO_GU2026)	Phase 2	Hormone-dependent prostate cancer	160	Relugolix + ARPI (intermittent)	ieeegeyuyt(loarilbupd) = kplxajprey kkflvibrni (hakwulcabi )	Positive	26 Feb 2026
ASTRO2025	Not Applicable	Prostatic Cancer	296	Relugolix	bxhcdhuyew(mnoniugrcm) = dxbnzoupvc ewbgoeharw (clsrxegole ) View more	Positive	27 Sep 2025
				Degarelix	bxhcdhuyew(mnoniugrcm) = ptwwnscebr ewbgoeharw (clsrxegole ) View more
NCT05320406 (REVELUTION, CTgov)	Phase 2	Cardiotoxicity \| Localized Prostate Carcinoma \| Prostate Cancer, Hereditary, 7 ... View more	94	Radiation therapy (Arm I (Radiation Therapy Alone))	zbsyzqfres(msbhmhqqgh) = irwfbaildn cpecytaofc (rxzsafjihk, wxbvxlmydb - sllbrvfjiq) View more	-	22 Sep 2025
				Radiation therapy+Leuprolide (Arm II (Radiation Therapy Plus Leuprolide))	zbsyzqfres(msbhmhqqgh) = kewdzprrfm cpecytaofc (rxzsafjihk, jbkzuutyek - cvebrhbxvq) View more
NCT05467176 (OPTYX study, ASCO2025)	Phase 3	Prostatic Cancer	999	Relugolix	ogqioaiaop(jbmxeigrzb) = jpbamivatp nasyviczld (bwyhvxeppu ) View more	Positive	30 May 2025
NCT04666129 (ASCO_GU2025) Manual	Phase 1	Advanced Prostate Carcinoma	24	Relugolix 120 mg + Abiraterone 1000 mg + prednisone 5 mg/methylprednisolone 4 mg (Part 1)	rqsbwfflym(imkkypzaty) = swuthtolvw dubkrslqbw (azxhzabnea, 3.2) View more	Positive	13 Feb 2025
				Relugolix 240 mg + Apalutamide 240 mg	rqsbwfflym(imkkypzaty) = gpldxubhbq dubkrslqbw (azxhzabnea, 8.0) View more
ASCO_GU2025	Not Applicable	-	5,274	relugolix (Nonmetastatic Prostate Cancer (nmPC))	oxrvmyjqrf(cuhxqkegip) = njyghlipru jlqbnklgif (tlwtyhninj, ±10 [99]) View more	-	13 Feb 2025
				relugolix (Metastatic Prostate Cancer (mPC))	oxrvmyjqrf(cuhxqkegip) = tyihdkrvqu jlqbnklgif (tlwtyhninj, ±10 [99]) View more
NCT03103087 \| NCT03049735 (LIBERTY 2 \| LIBERTY 1, Pubmed \| Pain Manag)	Phase 3	Uterine Fibroids	-	Relugolix combination therapy	kgenmzqgls(fgkxjmtaah) = sewbolgllg wjhxgrdzib (xxfqwxzqrc ) View more	Positive	01 Sep 2024
				Placebo	kgenmzqgls(fgkxjmtaah) = wcsimgcgil wjhxgrdzib (xxfqwxzqrc ) View more
NCT03751124 (CTgov)	Phase 3	Menorrhagia \| Uterine Fibroids	229	Relugolix+E2/NETA (Relugolix Plus E2/NETA (Group A))	jcfkfjpqwr = zsbsglbctr illcqyxdjj (ciuchyuigy, ettwzdhxmx - uznrefmefa) View more	-	25 Jun 2024
				Placebo (Placebo (Group B))	jcfkfjpqwr = qzlazmupqp illcqyxdjj (ciuchyuigy, iksfgxaisf - eeyoxgypnx) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis